Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 1,509.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,762 shares of the company’s stock after acquiring an additional 57,925 shares during the quarter. GAMMA Investing LLC’s holdings in Centessa Pharmaceuticals were worth $888,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CNTA. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals during the fourth quarter valued at about $31,000. Barclays PLC increased its position in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $162,000. OMERS ADMINISTRATION Corp bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $171,000. Finally, Shay Capital LLC bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $239,000. 82.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Piper Sandler began coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an “overweight” rating and a $38.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Chardan Capital initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 target price on the stock. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.89.

Insider Buying and Selling

In other news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $12.82, for a total transaction of $128,200.00. Following the completion of the sale, the insider now owns 122,279 shares of the company’s stock, valued at approximately $1,567,616.78. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Arjun Goyal acquired 44,939 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, May 15th. The stock was acquired at an average cost of $12.24 per share, with a total value of $550,053.36. Following the purchase, the director now directly owns 44,939 shares of the company’s stock, valued at $550,053.36. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 162,398 shares of company stock worth $2,332,552. Corporate insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $12.60 on Tuesday. The firm has a market capitalization of $1.68 billion, a P/E ratio of -8.24 and a beta of 1.48. Centessa Pharmaceuticals plc has a 12 month low of $8.46 and a 12 month high of $19.09. The business’s fifty day simple moving average is $12.62 and its 200 day simple moving average is $14.96. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.